Myriad Genetics and Sophia Genetics have entered a strategic collaboration to develop and commercialize a cancer liquid biopsy companion diagnostic (CDx) test. The partnership combines Myriad’s U.S.-based laboratory capabilities with Sophia’s extensive international network, initially focusing on the MSK-ACCESS powered assay developed with Memorial Sloan Kettering Cancer Center. The collaboration aims to provide biopharmaceutical partners with comprehensive CDx solutions enabling broader patient access to precision oncology treatments globally, supported by coordinated regulatory strategies in different regions.